July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Predictive factors for metamorphopsia after reduced-fluence photodynamic therapy in central serous chorioretinopathy patients with good visual acuity at baseline.
Author Affiliations & Notes
  • Mayuka Hayashida
    Kobe University, Kobe, Japan
  • Akiko Miki
    Kobe University, Kobe, Japan
  • Shunichiro Nakai
    Kobe University, Kobe, Japan
  • Wataru Matsumiya
    Kobe University, Kobe, Japan
  • Hisanori Imai
    Kobe University, Kobe, Japan
  • Sentaro Kusuhara
    Kobe University, Kobe, Japan
  • Makoto Nakamura
    Kobe University, Kobe, Japan
  • Footnotes
    Commercial Relationships   Mayuka Hayashida, None; Akiko Miki, None; Shunichiro Nakai, None; Wataru Matsumiya, None; Hisanori Imai, None; Sentaro Kusuhara, Kobe University (P); Makoto Nakamura, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5012. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mayuka Hayashida, Akiko Miki, Shunichiro Nakai, Wataru Matsumiya, Hisanori Imai, Sentaro Kusuhara, Makoto Nakamura; Predictive factors for metamorphopsia after reduced-fluence photodynamic therapy in central serous chorioretinopathy patients with good visual acuity at baseline.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5012. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate predictive factors for metamorphopsia after reduced-fluence photodynamic therapy (RFPDT) in central serous chorioretinopathy (CSC) patients with good visual acuity at baseline.

Methods : 26 eyes of 26 consecutive patients with resolved CSC after RFPDT and best-corrected visual acuity (BCVA) better than 0.6 (74 letters in ETDRS chart) were retrospectively reviewed. We measured metamorphopsia using M-CHARTS at 6 months after RFPDT. A greater one of the horizontal and vertical M-CHARTS scores was applied for the extent of metamorphopsia. Patients were divided into 2 groups depending on the presence or absence of metamorphopsia defined as M-CHARTS score equal to or greater than 0.5°; M (+) group (n=14, M-CHARTS score≧0.5°), or M (-) group (n=12, M-CHARTS score<0.5°). We investigated the differences in age, sex, time of duration, baseline BCVA, and findings of optical coherence tomography (OCT) between groups.

Results : Duration of symptom in M (+) group was significantly longer compared with that in M (-) group. (P=0.027). Outer nuclear layer (ONL) thickness before RFPDT was significantly thinner in M (+) group than M (-) group (P=0.020). In the multivariate analysis, thinner ONL thickness before RFPDT (P=0.014) was related to large metamorphopsia in CSC patients with good BCVA at baseline.

Conclusions : ONL thickness may be useful as predictive factors for metamorphopsia after RFPDT in CSC patients with good BCVA at baseline.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×